Initiation: Digital health pioneer
IXICO sells technologies and services for the analysis of brain disease. We expect strong growth mainly driven by the expansion of its clinical trial business into new indications, new markets and bigger contracts. It is also well placed to capitalise on the burgeoning use of digital technologies in disease management. Using DCF, we value IXICO at £10.7m or 62p/share.IXICO is a provider of technology enabled services to the global biopharmaceutical industry. Co.'s services are used to select patients for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.